Development and experience of using the transcriptional gene signature in the diagnosis of molecular breast cancer subtypes
- Авторлар: Burmenskaya O.V.1, Trofimov D.Y.1, Kometova V.V.1, Sergeev I.V.2, Maerle A.V.2, Rodionov V.V.1, Sukhikh G.T.1
-
Мекемелер:
- Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
- OOO "DNA-Technology Research Production Firm"
- Шығарылым: № 2 (2020)
- Беттер: 132-140
- Бөлім: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248800
- DOI: https://doi.org/10.18565/aig.2020.2.132-140
- ID: 248800
Дәйексөз келтіру
Аннотация
Толық мәтін
Авторлар туралы
Olga Burmenskaya
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: o_bourmenskaya@oparina4.ru
SD, Head of the Laboratory of Oncological Genetics
Dmitry Trofimov
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: d_trofimov@oparina4.ru
professor, SD, Director of the Institute of Reproductive Genetics
Vlada Kometova
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: v_kometova@oparina4.ru
MD, Senior Researcher, Pathology Department
Ilia Sergeev
OOO "DNA-Technology Research Production Firm"
Email: i.sergeev@dna-technology.ru
PhD, Head of Oligonucleotide synthesis department
Artem Maerle
OOO "DNA-Technology Research Production Firm"
Email: a.maerle@dna-technology.ru
Head of QC unit of Oligonucleotide synthesis department
Valery Rodionov
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: v_rodionov@oparina4.ru
MD, professor, Head of the Department of Breast Cancer Department
Genady Sukhikh
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: g_sukhikh@oparina4.ru
MD, Academician RAS, professor, Director
Әдебиет тізімі
- Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68(6): 394424. doi: 10.3322/caac.21492
- Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-52. https://doi.org/10.1038/35021093
- Paik S., Shak S., Tang G., Kim Ch., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl J. Med. 2004; 351(27): 2817-26. doi: 10.1056/NEJMoa041588
- Tian S., et al. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights. 2010; 5: 129-38. doi: 10.4137/BMI.S6184
- Tian S., Roepman P., Van’t Veer L.J., Bernards R., de Snoo F., Glas A.M., et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015; 24 Suppl 2: S26-35. doi: 10.4137/BMI.S6184.
- Goldhirsch A., Wood W.C., Coates A.S., et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22: 1736-1747. doi: 10.1093/annonc/mdr304.
- Кулигина Е.Ш. Эпидемиологические и молекулярные аспекты рака молочной железы. Практическая онкология. 2010; 11(4): 203-16.
- Nielsen T.O., Parker J.S., Leung S., Voduc D., Ebbert M., Vickery T., Davies S.R., Snider J., Stijleman I.J., Reed J., Cheang M.C., Mardis E.R., Perou C.M., Bernard P.S., Ellis M.J. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010; 16(21): 5222- 32. doi: 10.1158/1078-0432.CCR-10-1282
- Guiu S., Michiels S., Andre F., Cortes J., Denkert C., Di Leo A., et al. Molecular subclasses of breast canсer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol. 2012; 23: 2997-3006. doi: 10.1093/annonc/mds586
- Curigliano G., Burstein H.J., Winer E.P., et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8):1700-12. doi: 10.1093/annonc/mdx308.
- Polley M.Y., Leung S.C., Gao D., et al. An international study to increase concordance in Ki67 scoring. Mod Pathol. 2015; 28: 778-86. doi: 10.1038/ modpathol.2015.38
- Polley M.Y., Leung S.C., McShane L.M., et al. An international Ki67 reproducibility study. J. Natl Cancer Inst. 2013; 105: 1897-1906. doi: 10.1093/ jnci/djt306